Last reviewed · How we verify
Brigatinib in ALK-positive NSCLC Identified Via Blood-based Assays
This is single-arm, open-label study design. Patients will receive brigatinib until disease progression, unacceptable toxicity, withdrawal of consent, of death.
Details
| Lead sponsor | JI-YOUN HAN |
|---|---|
| Phase | PHASE2 |
| Status | UNKNOWN |
| Enrolment | 35 |
| Start date | Fri May 15 2020 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Mon Mar 31 2025 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Non Small Cell Lung Cancer
Interventions
- Brigatinib
Countries
South Korea